Lucid Diagnostics
$1.39
22
+$0.01+1.09% Today
Statistics
Day High
-
Day Low
-
52W High
1.88
52W Low
1.04
Volume
132,223
Avg. Volume
32,130
Mkt Cap
61.86M
P/E Ratio
-0.99
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12MarExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.41
-0.27
-0.14
0
Expected EPS
-0.25
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow LUCD. It's not an investment recommendation.
Analyst Ratings
3.25$Average Price Target
The highest estimate is $4.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Show more...
CEO
Country
US
ISIN
US54948X1090